These medicines, including liraglutide, albiglutide, dulaglutide, and semaglutide, were synthesised using strategic changes of the human GLP-1 molecule to diminish its vulnerability to DPP-4 breakdown
Furthermore, originators hold dozens of patents on the physical delivery devices (the pens), creating a multi-layered legal fortress
S.JungH
Increasingly, drugs in this category are no longer defined by GLP1 activity alone and target multiple hormones
As such, its easy to think that combining them will double down on the results
Retatrutide is a synthetic 39-amino acid acylated peptide designed as a triple agonist targeting the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide recepto